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In a previous cross-sectional study (1), we
showed that past (i.e., an average of 16 years
before study enrollment) occupational expo-
sure to organic and inorganic lead, as mea-
sured in tibia by X-ray fluorescence, was
associated with poorer performance on neu-
robehavioral tests. We observed a stronger
association in the domains of manual dexter-
ity, executive ability, and verbal memory.
Function in these same domains is also
declining over time in relation to tibia lead
(2). In this population, the effect of adult
lead exposure on central nervous system
(CNS) function appears to be progressive,
possibly mediated by permanent CNS
changes involving cellular damage.
The specific mechanisms mediating the
relation of past adult lead exposure on the
adult CNS are not known. Nonetheless,
these findings and other evidence support
the notion that the effect of past exposure to
lead in adults is progressive and, as a conse-
quence, must be mediated by permanent
CNS changes that are likely to involve cellu-
lar damage and associated pathophysiologic
responses. In this regard, epidemiologic and
pathophysiologic evidence indicates that the
short- and long-term consequences of physi-
cal insults to the CNS (e.g., traumatic brain
injury) are inﬂuenced by whether or not an
individual has at least one ε4 allele for the
apolipoprotein E (ApoE) gene (3–7).
We considered whether the effect modi-
fication of the ApoE-ε4 allele that has been
observed with traumatic brain injury was
generalizable to the changes induced by past
exposure to lead. To test this hypothesis, we
used data from a previous cross-sectional
study of former organolead manufacturing
workers (1) on whom ApoE genotyping had
been completed. We specifically evaluated
whether tibia lead levels have a larger inﬂu-
ence on neurobehavioral test scores in sub-
jects with the ApoE-ε4 allele compared to
those without the allele.
Methods
Study design and overview. We derived data
from a longitudinal study of CNS and periph-
eral nervous system function in former
employees of a chemical manufacturing facility
in the eastern United States that, in the past,
produced tetraethyl and tetramethyl lead. The
methods are described in detail elsewhere (1,2).
Here we report on a cross-sectional
analysis of data from an original cohort of
544 individuals for whom we measured cog-
nitive function and tibia lead. We obtained
ApoE genotype on 529 of the 544 cohort
members. The study was reviewed and
approved by the Johns Hopkins Bloomberg
School of Public Health Committee on
Human Research, and written informed
consent was obtained from all participants.
Selection and recruitment of study sub-
jects. Study participants worked in a plant
that manufactured a broad range of chemical
products; the present study focused on indi-
viduals who were ever employed in the plant
area that manufactured tetraethyl lead from
1923 to 1991 and tetramethyl lead from
1960 to 1983 (8). None of the subjects
recruited for this study were occupationally
exposed to lead at the time of enrollment.
Subjects were eligible for recruitment if they
were ever employed in the facility on or after
1 January 1950, were male, and were
between 40 and 70 years of age in 1995. Of
an estimated 968 eligible subjects, we
enrolled 73% (n = 703) in the study.
Data collection. We read the consent
statement to subjects who completed a clinic
visit. After obtaining consent, we collected
data in the following order: Symptom
CheckList-90 (SCL-90) (9), blood pressure,
height, weight, an initial interview (i.e.,
demographics, problems with vision or hear-
ing, medical history, use of nonsteroidal
anti-inflammatory drugs, history of head,
hand, or finger injuries, physical activity
level), neurobehavioral testing, the Center for
Epidemiologic Study Depression scale (CES-
D) (10), the Scandinavian Questionnaire 16,
and an exit interview (i.e., occupational his-
tory, smoking history, alcohol consumption
history). The neurobehavioral test battery has
been described in detail elsewhere (1,2). We
completed the initial visit by obtaining two
10-mL blood specimens by venipuncture. In
a separate visit, we also measured tibia lead.
Tibia lead and ApoE genotype. We mea-
sured tibia lead for 30 min (true time) using
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Our objective in this study was to determine if the known relation between tibia bone lead levels
and neurobehavioral test scores are inﬂuenced by the apolipoprotein E (ApoE) genotype. We col-
lected data on 20 neurobehavioral tests in 529 former organolead workers who had an average of
16 years since last occupational exposure to lead. We used linear regression to model the relations
between each of 20 neurobehavioral test scores and tibia lead, a binary variable for ApoE genotype
(i.e., at least one ε4 allele vs. none), and an interaction term between tibia lead and the binary
term for ApoE genotype. At the time of testing, former lead workers were an average of 57.6 years
of age; 82% were younger than 65 years. In regression analysis, we observed one statistically sig-
niﬁcant and one borderline signiﬁcant coefﬁcient for ApoE genotype alone. Coefﬁcients for the
ApoE and tibia lead interaction term were negative in 19 of the 20 regression models. This indi-
cates that the slope for the relation between tibia lead and each neurobehavioral test was more
negative for individuals with at least one ε4 allele than for those who did not have an ε4 allele.
Four of 19 negative coefﬁcients for the interaction term were statistically signiﬁcant (digit sym-
bol, Purdue pegboard assembly, Purdue pegboard-dominant hand, complex reaction time);
another three of the remaining 16 coefﬁcients (symbol digit, trail-making A, Stroop) were border-
line signiﬁcant (i.e., p < 0.10). This study suggests that individuals may vary in susceptibility to
the long-term effects of lead on the central nervous system (CNS). In particular, the persistent
CNS effect of lead may be more toxic in individuals who have at least one ApoE-ε4 allele. Key
words: apolipoprotein E, bone lead, cognitive function, neurobehavioral tests, X-ray
ﬂuorescence.Environ Health Perspect 110:501–505 (2002). [Online 2 April 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p501-505stewart/abstract.html109Cd to ﬂuoresce the k-shell X ray of lead.
We measured lead at the left midtibia shaft
(11–14). Because of large interindividual dif-
ferences in time since last occupational lead
exposure, we used years since last exposure
to estimate tibia lead levels at the termina-
tion of lead exposure, termed peak tibia lead.
We extrapolated current tibia lead levels
using a clearance half-time of lead in tibia of
27 years (15), assuming first-order (mono-
exponential) clearance from tibia (1). We
have shown that peak tibia lead is the
strongest predictor of the cognitive effects of
lead and that it offers the best approximation
of the area under the exposure curve
reﬂected by the duration of exposure multi-
plied by mean exposure intensity (16).
We completed ApoE genotyping using
the method of Hixson and Vernier (17).
We carried out reactions in a total volume
of 50 µL with 2.5 µM primer, 0.2 µM
deoxyribonucleoside triphosphate, 1.5 mM
MgCl2, 0.25 µL (1.25 U) of Taq poly-
merase, and 10% dimethyl sulfoxide.
Cycling was 95oC for 30 sec, 60oC for 30
sec, and 71oC for 1 min for 40 rounds. The
polymerase chain reaction product was
digested by HhaI and run on 4% agarose
gels for genotype determination. Primers
were F4-ACAGAATTCGCCCCGGC-
CTGGTAC and F6-TAAGCTTGGCAC-
GGCTGTCCAAGGA.
Statistical analysis. We previously showed
that peak tibia lead is consistently associated
with poorer performance on neurobehavioral
tests (1). We limited the present analysis to
evaluating whether ApoE genotype modiﬁed
the relations between peak tibia lead and neu-
robehavioral test scores using data from a sin-
gle visit (i.e., at cross section).
We examined neurobehavioral measures
for outliers attributable to stroke, head
injury, and other organic conditions or phys-
ical impairments, and evaluated variable dis-
tributions for normality. We standardized all
neurobehavioral test scores for directionality
so that a negative coefficient in the model
indicates that performance on a neurobehav-
ioral test was worse with increasing lead
exposure or dose. Distributions of scores for
five neurobehavioral tests evidenced depar-
tures from normality. Before modeling, we
transformed the Stroop test as the square
root, and log-transformed four other tests
(trail-making A and B, choice reaction time,
and SCL-90 Global Severity Index).
We used generalized linear models (18) to
examine the relations of peak tibia lead, ApoE
genotype (at least one ε4 allele vs. none), and
the cross product of peak tibia lead and ApoE
genotype with neurobehavioral test scores. We
could not address questions about one versus
two ε4 alleles because only six individuals had
two ε4 alleles. Other variables in the model
included age (linear and quadratic terms), race
(white vs. other race/ethnicity), education (less
than high school, high school diploma, some
college, college degree, graduate training), test-
ing technician (four technicians), duration of
occupational lead exposure (in years), and
depression status as measured by the CES-D
(< 16, ≥ 16) (10). We excluded individuals if
they had a recent history (i.e., stroke, hand
injury for selected tests) that could inﬂuence
performance on neurobehavioral tests.
Results
Demographic and exposure profile. The
demographic and exposure proﬁle of the pop-
ulation has been previously described (1,2). In
this section, we focus on differences by ApoE
genotype. The most common genotype vari-
ant among the 529 study participants was
ε3ε3 (67.1%), followed in order by ε3ε4
(18.0%), ε2ε3 (10.4%), ε2ε4 (3.2%), ε4ε4
(1.1%), and ε2ε2 (0.2%). For the analysis,
we categorized individuals as not having an
ε4 allele (n = 411; 77.7%) and having at
least one ε4 allele (n = 118; 22.3%). We
observed no differences between individuals
with and without an ApoE-ε4 allele for age,
education, time since last exposure, or tibia
lead levels (Table 1). As expected (19,20), we
observed a statistically signiﬁcant difference in
ApoE-ε4 allele prevalence by race (p = 0.003);
43% of nonwhites, predominantly African
Americans, had at least one ApoE-ε4 allele
compared to 21% of whites. Individuals with
at least one ApoE-ε4 allele tended to work for
a longer period of time in the organolead
facility compared to those without the ε4
allele (p = 0.06).
ApoE genotype, peak tibia lead, and
neurobehavioral function. In a previous
analysis (1), peak tibia lead coefﬁcients were
negative for all 20 neurobehavioral tests.
Higher peak tibia lead levels were signifi-
cantly (p < 0.05) associated with poorer per-
formance on 11 of the 20 tests.
In the present analysis, we added a binary
variable for ApoE genotype (i.e., presence or
absence of at least one ε4 allele) to the model
in the absence of tibia lead. Twelve of the 20
coefﬁcients for ApoE genotype were negative
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Table 1. Percentage distributions and mean ± SD of selected study variables by ApoE-ε4 allele status in 529
former organolead workers in whom tibia lead and neurobehavioral function were measured in 1996–1997.
Number of ApoE-ε4 alleles
None At least one
Variable/category (n = 411) (n = 118)
Age* (years)
40–49 18.0 16.1
50–54 20.7 19.5
55–59 22.6 22.0
60–64 22.2 15.3
65–69 12.4 17.8
≥ 70 4.1 9.3
Mean ± SD 57.3 ± 7.4 58.5 ± 7.8
Education*
Less than high school 7.5 8.5
High school diploma or equivalent 58.4 61.9
Some college or technical school 29.2 24.6
College degree 4.9 5.1
Race**
White 95.1 87.3
Not white  4.9 12.7
Exposure duration* (years)
< 1 22.4 17.8
1–2.99 23.1 19.5
3–4.99 12.9 9.3
5–9.99 14.4 25.4
≥ 10 27.2 28.0
Mean ± SD 8.1 ± 9.7 8.8 ± 10.0
Time since last exposure to lead* (years)
< 5 16.1 14.4
5–9.99 18.3 20.3
10–14.99 13.9 8.5
≥ 15 51.7 56.8
Mean ± SD 17.9 ± 11.6 17.9 ± 11.4
Peak tibia lead* (µg Pb/g bone mineral)
< 5 10.5 5.1
5–9.99 11.0 14.5
10–14.99 13.4 9.4
15–19.99 16.6 14.5
≥ 20 48.5 56.4
Mean ± SD 23.1 ± 16.9 26.2 ± 19.1
*The difference by ApoE genotype was not statistically signiﬁcant (p > 0.10), as assessed by t-test for continuous variable
comparisons or chi-square for categorical variable comparisons. **p ≤ 0.01.(model I, Table 2); one of the negative coef-
ficients was statistically significant (i.e.,
Stroop), and one other was borderline signif-
icant (i.e., trail-making B; p < 0.10).
Coefficients for ApoE genotype were not
substantially changed after adding peak tibia
lead to each of the 20 models (model II,
Table 2). We subsequently added a cross-
product term for ApoE genotype and peak
tibia lead to each model. Nineteen of the 20
coefficients for the interaction term were
negative (model III, Table 2); 4 of the 20
coefﬁcients were signiﬁcant (p < 0.05), and 7
had associated p-values < 0.10.
To interpret the magnitude of the effect
from the interaction of ApoE-ε4 with tibia
lead, we compared the coefficients for the
interaction term to the coefficient for tibia
lead alone (i.e., slope for the relation
between tibia lead and neurobehavioral test
score) for the seven tests where we observed
a statistically significant or borderline sig-
nificant effect. ApoE-ε4–positive status
appears to increase the slope for the relation
between tibia lead and neurobehavioral test
scores by 1-fold (i.e., Stroop) to 4-fold (i.e.,
trail-making A), with a 2-fold increase as
the median.
Discussion
Negative coefﬁcients for the interaction term
in this analysis indicate that peak tibia lead
levels may have a greater adverse influence
on neurobehavioral test scores in subjects
with the ApoE-ε4 allele compared to those
without the allele. Previous studies have
shown that ApoE genotype modifies the
effect of physical insults on the long-term
risk of dementia (3,6) and risk of dementia
after stroke (21). The results of this study
suggest that the effect-modifying pathophys-
iologic role of the ApoE-ε4 allele in the CNS
may be extended to include the long-term
effects of adult exposure to lead.
The ApoE genotype appears to play a role
in the acute and long-term recovery from
physical insults. Elevated β-amyloid deposits
have been observed in humans during the
acute phase of recovery from traumatic brain
injury (22,23), deposits that appear more
pronounced in those with the ApoE-ε4 allele
(4). The ε4 allele is also associated with
delayed recovery from trauma-induced
coma (5,7) and risk of dementia among
individuals with a history of brain trauma
(3,6), especially if the brain trauma occurs
at a later age (3).
The data from this study suggest that
ApoE genotype may modify the relation
between peak tibia lead and neurobehavioral
function. Speciﬁcally, slopes for the relations
between peak tibia lead and neurobehavioral
test scores were more negative (i.e., more
adverse) for individuals with at least one
ApoE-ε4 allele. We observed the strongest
and most consistent associations for the
interaction term for measures of executive
ability, a ﬁnding that differs to some degree
from what we observed (1) for the main
effect of tibia lead alone (i.e., manual dexter-
ity followed, in order, by verbal memory and
learning, and executive ability). These con-
trasting findings may reflect differences in
the local anatomic pathophysiology induced
by lead alone (e.g., due to the selective depo-
sition of lead), by ApoE genotype alone (e.g.,
where Alzheimer-related pathology is likely
to first emerge), or by the combination of
lead and ApoE genotype (e.g., overlapping
CNS regions).
The interaction between the ApoE-ε4
allele and past exposure to lead suggested by
our data is particularly noteworthy given that
an average of 16 years had passed between
the last time individuals were occupationally
Articles • ApoE genotype, lead exposure, and neurobehavior
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Table 2. Linear regression coefﬁcientsa (SE) for peak tibia lead, ApoE genotype (at least one ε4 allele vs. none), and the interaction between peak tibia lead and
ApoE genotype as predictors of neurobehavioral test scores in former organolead workers, 1997.
Model I Model II Model III
ApoE-ε4 Peak tibia lead ApoE-ε4 Peak tibia Lead ApoE-ε4 Interaction  termb
Domain/neurobehavioral testc β (SE β)d β (SE β)d β (SE β)d β (SE β)d β (SE β)d β (SE β)d
Visuo-construction/visuo-perception
Block design (WAIS) 0.784 (0.917) –0.039 (0.026) 0.933 (0.921) –0.029 (0.029) 1.877 (1.555) –0.037 (0.049)
Rey complex ﬁgure, copy 0.201 (0.452) –0.015 (0.013) 0.291 (0.454) –0.005 (0.014) 1.236 (0.765) –0.040 (0.024)
Verbal intelligence
Vocabulary (WAIS-R) 0.788 (1.000) –0.063 (0.028)** 1.010 (1.000) –0.066 (0.031)** 0.718 (1.688) 0.012 (0.054)
Verbal memory and learning
Serial digit learning –0.867 (0.737) –0.048 (0.021)** –0.723 (0.739) –0.045 (0.023) –0.428 (1.248) –0.012 (0.040)
Rey auditory verbal learning test
Immediate recall –0.474 (0.949) –0.068 (0.026)** –0.149 (0.944) –0.063 (0.030)** 0.333 (1.587) –0.019 (0.051)
Recognition –0.217 (0.320) –0.016 (0.009)* –0.193 (0.321) –0.014 (0.010) –0.023 (0.542) –0.007 (0.018)
Delayed recall 0.125 (0.327) –0.011 (0.009) 0.187 (0.328) –0.006 (0.010) 0.613 (0.552)  –0.017 (0.018)
Visual memory
Symbol digit (WAIS-R) –0.300 (0.482) –0.017 (0.014) –0.216 (0.483) –0.004 (0.015) 0.946 (0.812) –0.046 (0.026)*
Rey complex ﬁgure, delayed recall 0.630 (0.538) –0.025 (0.015)* 0.720 (0.540) –0.017 (0.017) 1.477 (0.910) –0.030 (0.029)
Executive ability
Digit symbol substitution –0.729 (0.990) –0.027 (0.028) –0.587 (0.994)  0.001 (0.031) 2.149 (1.678) –0.109 (0.054)**
Trail making
Part Ae 0.570 (3.063) –0.068 (0.086) 1.086 (3.077) 0.013 (0.096) 8.755 (5.174)* –0.303 (0.164)* 
Part Be –0.058 (0.034)* –0.001 (0.001) –0.053 (0.034) –0.001 (0.001) –0.013 (0.061) –0.002 (0.002) 
Purdue pegboard, assembly –1.049 (1.825) –0.122 (0.050)** –0.490 (1.819) –0.074 (0.056) 4.241 (3.058) –0.189 (0.098)**
Stroop (C form–A form)e –0.341 (0.148)**  –0.013 (0.004)** –0.315 (0.147)** –0.010 (0.005)** 0.014 (0.248) –0.013 (0.008)*
Manual dexterity
Finger-tapping
Dominant hand –0.436 (0.731)  –0.033 (0.020)* –0.252 (0.732) –0.030 (0.023) 0.086 (1.229) –0.014 (0.040)
Non-dominant hand –0.251 (0.651)  –0.045 (0.018)** –0.136 (0.651) –0.041 (0.020)** 0.307 (1.094) –0.018 (0.035)
Purdue pegboard
Dominant hand 0.311 (0.521)  –0.036 (0.014)** 0.441 (0.521) –0.019 (0.016) 2.127 (0.869)** –0.068 (0.028)**
Non-dominant hand –0.124 (0.516) –0.046 (0.014)** 0.023 (0.513) –0.035 (0.016)** 1.070 (0.861) –0.042 (0.028)
Both hands 0.010 (0.458) –0.035 (0.013)** 0.145 (0.456) –0.028 (0.014)** 0.843 (0.765) –0.028 (0.025)
Psychomotor
Complex reaction time (msec)e –0.004 (0.020) –0.001 (0.001) –0.002 (0.020) 0.000 (0.001) 0.061 (0.033)* –0.003 (0.001)**
Abbreviations: WAIS, Wechsler Adult Intelligence Scale; WAIS-R, Wechsler Adult Intelligence Scale-Revised.
aAdjusted for age (linear and squared terms), race, education level, CES-D score (i.e., depression status), testing technician, and visit number. bCross-product term of peak tibia lead and
ApoE genotype. cAll measures have been standardized so that a negative coefﬁcient indicates that neurobehavioral test scores are worse as exposure or dose increases. dThe β coefﬁ-
cient from the regression model and its SE. eThese tests were transformed before modeling due to departures from normality. *p ≤ 0.10; **p ≤ 0.05.exposed to lead and enrollment in the study.
If this interaction is real, it cannot be
explained by an acute effect of lead. Rather,
past lead exposure may have induced persis-
tent (1,2) and progressive (2) changes, a view
that is consistent with an effect-modifying
role of ApoE genotype and the suspected bio-
logic effects of organic and inorganic lead.
Several possible mechanism may explain the
observed interaction.
Triethyl lead, the first dealkylated
metabolite of tetraethyl lead, inhibits oxida-
tive phosphorylation, amino acid metabo-
lism, glucose oxidation, phosphocreatine
synthesis, and neurotransmitter metabolism
(24). Triethyl lead also inhibits microtubule
synthesis, leading to the clumping and
shrinking of cells, with vacuolar degenera-
tion and cellular necrosis (25). Tetraethyl
lead is converted to inorganic lead in rat
brain (26,27).
Lead appears to induce cell damage that
could explain, in part, persistent morphologic
changes observed in animal experimental
studies. Glial ﬁbrillary acidic protein, a cell-
specific cytoskeletal intermediate filament
protein used as a marker of number and size
of astrocytes, increases in the hippocampus of
animals dosed with either organic or inor-
ganic lead (28–30). Moreover, morphologic
changes in the CNS have been observed in
the rat hippocampus even at low lead levels
(31,32). Lead may have both a selective and a
general effect on CNS function. After injec-
tion of tetraethyl lead in rabbits, degenerative
changes and neuroﬁbrillary tangles have been
observed in the pyramidal cells of the frontal
cortex and hippocampus (26,33,34).
Evidence consistently shows that lead prefer-
entially, but not exclusively, affects the pre-
frontal cerebral cortex, hippocampus, and
cerebellum (35–47).
The neurobehavioral deficits that were
associated with tibia lead levels directly differ
to some degree from those that were signiﬁ-
cantly associated with the interaction term
for tibia lead and ApoE. Ultimately, we are
faced with the limitation that specific
domains of function cannot be uniquely
mapped to defined brain regions given the
battery of neurobehavioral tests that we
used. This limitation raises challenges in for-
mulating a biologic rationale that accounts
for the differences we have observed for tibia
lead alone versus tibia lead and ApoE geno-
type. Imaging studies (i.e., volumetric and
brain activity measures) in this population
may be helpful in validating the neurobehav-
ioral ﬁndings and providing the foundation
for a more speciﬁc biologic rationale to sup-
port the interaction between the ApoE-ε4
allele and past exposure to lead.
We did not observe a direct effect of
ApoE genotype (i.e., without terms for a main
effect of peak tibia lead or for an interaction
between lead and ApoE) on cognitive func-
tion. The absence of signiﬁcant ﬁndings may
be explained by the relatively young age of
study participants. At the time of testing (for
most subjects, we used the third study visit in
this analysis, the time of bone lead measure-
ment), individuals were, on average, 57.6
years of age with a range from 41 to 73 years;
82% of the population was < 65 years of age.
This explanation is consistent with the rela-
tion that we observed between neurobehav-
ioral test scores and the cross-product term for
ApoE genotype and age. We observed signiﬁ-
cant (i.e., p < 0.05) or borderline signiﬁcant
(i.e., p < 0.10) negative coefficients for the
interaction term for 10 of the 20 neurobehav-
ioral tests. This ﬁnding indicates that a mea-
surable effect of the ApoE-ε4 allele on
neurobehavioral function is detectable at
older but not necessarily younger ages.
In conclusion, the results of this study
support the notion that individuals may vary
in susceptibility to the long-term effects of
lead on the CNS. In particular, the persistent
CNS effect of lead may be more toxic in indi-
viduals who have at least one ApoE-ε4 allele.
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